Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients

Carlos Fernández-Díaz, Javier Loricera, Santos Castañeda, Raquel López-Mejías, Clara Ojeda-García, Alejandro Olivé, Samantha Rodríguez-Muguruza, Patricia E Carreira, Trinidad Pérez-Sandoval, Miriam Retuerto, Evelin C Cervantes-Pérez, Bryan J Flores-Robles, Blanca Hernández-Cruz, Ana Urruticoechea, Olga Maíz-Alonso, Luis Arboleya, Gema Bonilla, Íñigo Hernández-Rodríguez, Desirée Palma, Concepción Delgado, Rosa Expósito-Molinero, Ana Ruibal-Escribano, Belén Álvarez-Rodríguez, Juan Blanco-Madrigal, José A Bernal, Paloma Vela-Casasempere, Manuel Rodríguez-Gómez, Concepción Fito, Francisco Ortiz-Sanjuán, Javier Narváez, Manuel Moreno, Mireia López-Corbeto, Natalia Mena-Vázquez, Clara Aguilera-Cros, Susana Romero-Yuste, Sergi Ordóñez, Ignacio Villa-Blanco, M Carmen Gonzélez-Vela, Víctor Mora-Cuesta, Natalia Palmou-Fontana, José L Hernández, Miguel A González-Gay, Ricardo Blanco

Interstitial lung disease (ILD) is one of the most serious complications of rheumatoid arthritis (RA). In the present study, we aimed to assess the efficacy of abatacept (ABA) in patients with ILD associated to RA. National multicenter, non-controlled, open-label registry study of RA patients with ILD treated with ABA. 63 patients (36 women) with RA-associated ILD undergoing ABA therapy were studied. The mean ± standard deviation age at the time of the study was 63.2 ± 9.8 years. The median duration of RA and ILD from diagnosis were 6.8 and 1 year, respectively. RA was seropositive in 55 patients (87.3%). In 15 (23.8%) of 63 patients the development of ILD was closely related to the administration of synthetic or biologic disease modifying anti-rheumatic drugs. After a follow-up of 9.4 ± 3.2 months, two-thirds of patients remained stable whereas one-quarter experienced improvement in the Modified Medical Research Council scale. At that time forced vital capacity remained stable in almost two-thirds of patents and improved in one out of five patients assessed. Also, diffusing capacity of the lung for carbon monoxide remained stable in almost two-thirds and showed improvement in a quarter of the patients assessed. At 12 months, 50% of the 22 patients in whom chest HRCT scan was performed due persistence of respiratory symptoms showed stabilization, 8 (36.4%) improvement and 3 worsening of the HRCT scan pattern. Eleven of 63 patients had to discontinue ABA, mainly due to adverse events. ABA appears to be an effective in RA-associated ILD.